Private EquityScreenerRefer

MARKET INSIGHTS

  • EventsNEWPrivate market milestones
  • NewsPrecize daily pulse
  • BlogsIn-depth articles and opinions

GUIDES

Explore Now
  • Unlisted SharesStep-by-step · KYC
  • BuyingStep-by-step · KYC
  • SellingExit in 24 - 48 hours
  • Pre-IPOReturns · risks · case studies
  • Tax GuideBudget 2026 changes
  1. Home
  2. Unlisted share news
  3. S3V Vascular Technologies – Launches Indigenous Transcatheter Aortic Va…

S3V Vascular Technologies – Launches Indigenous Transcatheter Aortic Valve Replacement System

12 Mar 2026

Add as preferred source
Key Takeaways

Key Takeaway:
S3V’s indigenous TAVR system could significantly lower device costs and expand access to advanced cardiac treatment in India, addressing a large unmet demand where only ~4,000 procedures are performed annually against a need of ~50,000.

Key Takeaway:
S3V’s indigenous TAVR system could significantly lower device costs and expand access to advanced cardiac treatment in India, addressing a large unmet demand where only ~4,000 procedures are performed annually against a need of ~50,000.

S3V Vascular Technologies

S3V Vascular Technologies

0.00%

Expert Analysis

Expert Analysis:

  • S3V Vascular Technologies, backed by former L&T chairman A.M. Naik along with investors Utpal Sheth and Madhu Kela, has unveiled India’s first indigenous balloon-expandable Transcatheter Aortic Valve Replacement (TAVR) system.

  • TAVR is a minimally invasive alternative to open-heart surgery used to treat severe aortic stenosis and is widely adopted globally for elderly or high-risk patients.

  • The domestically engineered device aims to reduce dependence on imported heart-valve implants, which currently cost ₹13 lakh to ₹23 lakh per device, significantly limiting access to the procedure in India.

  • India currently performs around 4,000 TAVR procedures annually, despite an estimated clinical demand of nearly 50,000 cases, highlighting the large treatment gap the innovation seeks to address.

  • The system has entered preclinical testing, and subject to regulatory approvals, the company expects a commercial rollout within 12–18 months.

Publisher:Money Control